Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases. It is being evaluated in clinical trials for adult-onset leukodystrophy with neuroaxonal spheroids (ALSP) and related Parkinsonism syndromes. Inhibikase has also advanced IKT-013, another oral kinase inhibitor, into early-stage development for broader applications in adult-onset neurodegenerative conditions.

Beyond its lead programs, Inhibikase is progressing additional preclinical assets aimed at treating lysosomal storage disorders and other rare neurological diseases. The company leverages collaborations with academic institutions and clinical research centers in North America and Europe to support its translational and clinical development efforts. Strategic partnerships are intended to accelerate the transition from laboratory research to human trials.

Inhibikase’s management team combines expertise in neurology, drug development and regulatory affairs. The company engages with patient advocacy groups and scientific advisors to refine its development strategy and ensure its therapies address critical gaps in treatment. As a publicly traded company, Inhibikase remains committed to delivering novel therapeutic options for patients suffering from debilitating neurodegenerative disorders.

Key Stats

• Today's Range: $1.57 to $1.65
• 50-Day Range: $1.43 to $1.89
• 52-Week Range: $1.15 to $4.20
• Volume: 51,702 shs
• Average Volume: 180,332 shs
• Market Capitalization: $120.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Moderate Buy

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 813th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Inhibikase Therapeutics has a consensus price target of $6.50, representing about 301.2% upside from its current price of $1.62.

Amount of Analyst Coverage

Inhibikase Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibikase Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibikase Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IKT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IKT.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

IKT Stock Analysis - Frequently Asked Questions

How have IKT shares performed this year?

Inhibikase Therapeutics' stock was trading at $3.25 at the beginning of the year. Since then, IKT stock has decreased by 50.2% and is now trading at $1.62.

How were Inhibikase Therapeutics' earnings last quarter?

Inhibikase Therapeutics, Inc. (NYSE:IKT) released its quarterly earnings data on Monday, November, 15th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.24. The business had revenue of $0.33 million for the quarter.

When did Inhibikase Therapeutics' stock split?

Inhibikase Therapeutics's stock reverse split on Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did Inhibikase Therapeutics IPO?

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Inhibikase Therapeutics?

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inhibikase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 10/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IKT
• CIK: 1750149
• Web: www.inhibikase.com
• Phone: 678-392-3419
• Fax: N/A
• Employees: 6
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Inhibikase Therapeutics: $6.50
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +301.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.03 million
• Net Margins: N/A
• Pretax Margin: -22,978.75%
• Return on Equity: -350.63%
• Return on Assets: -201.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 74,517,000
• Free Float: 66,178,000
• Market Cap: $120.72 million
• Optionable: Not Optionable
• Beta: 0.89